Ablynx receives €1.2 million grant to further advance its anti-IL-6R programme, ALX-0061

23-Feb-2010 - Belgium

Ablynx announced that it has been awarded a grant worth €1.2 million by the Flemish agency for Innovation by Science and Technology (IWT).

The grant supports Ablynx in accelerating the development of its Nanobody-based programme, ALX-0061, into clinical development for the treatment of autoimmune and inflammatory diseases.

ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. Due to its monovalent binding to the target, it also does not have the potential to crosslink the IL-6R target which may have some benefits compared with monoclonal antibody approaches.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances